Norbert Volkmar
Apr 24, 2020; 133:jcs243519-jcs243519
REVIEW

Full Text:

Many people turn to the Internet to find a Mr. or Ms. Right. But lemurs just give their potential partners a sniff. A study of lemur scents has found that an individual’s distinctive body odor reflects genetic differences in their immune system, and that other lemurs can detect these differences by smell. From just one whiff, these primates can tell which prospective partners have immune genes different from their own. The ability to sniff out mates with different immune genes could make their offspring’s immune systems more diverse and able to fight more pathogens. Shown here: Fritz the ring-tailed lemur sniffs a tree for traces of other lemurs’ scents.

Image credit: David Haring/Duke Lemur Center

Full Text:

How do galaxies such as our Milky Way come into existence? How do they grow and change over time? The science behind galaxy formation has long been a puzzle, but a University of Arizona-led team of scientists is one step closer to finding answers, thanks to supercomputer simulations. Observing real galaxies in space can only provide snapshots in time, so researchers who study how galaxies evolve over billions of years need to use computer simulations. Traditionally, astronomers have used simulations to invent theories of galaxy formation and test them, but they have had to proceed one galaxy at a time. Peter Behroozi of the university's Steward Observatory and colleagues overcame this hurdle by generating millions of different universes on a supercomputer, each according to different physical theories for how galaxies form. The findings challenge fundamental ideas about the role dark matter plays in galaxy formation, the evolution of galaxies over time and the birth of stars. The study is the first to create self-consistent universes that are exact replicas of the real ones -- computer simulations that each represent a sizeable chunk of the actual cosmos, containing 12 million galaxies and spanning the time from 400 million years after the Big Bang to the present day. The results from the "UniverseMachine," as the authors call their approach, have helped resolve the long-standing paradox of why galaxies cease to form new stars even when they retain plenty of hydrogen gas, the raw material from which stars are forged. The research is partially funded by NSF's Division of Physics through grants to UC Santa Barbara's Kavli Institute for Theoretical Physics and the Aspen Center for Physics.

Image credit: NASA/ESA/J. Lotz and the HFF Team/STScI

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Peter Krauth for Streetwise Reports   05/05/2020

Gold has the wind in its sails. Its price in U.S. dollars is up an astounding 62% since late 2015, with a 33% gain in just the past year, outpacing all major assets.

And investors are only just starting to get interested.

The Covid-19 pandemic and its economic impact is a major catalyst. More than $8 trillion in global fiscal stimulus has already been committed to alleviate unemployment and support struggling businesses. But it's almost certainly not enough.

"That sets up the perfect storm for X-Terra, making it a Strong BUY. With its outstanding initial drill results at the Grog property and the remarkable potential at Troilus East, I can easily see XTT double its market cap in the next 6-12 months, perhaps sooner."

Near-zero interest rates combined with unprecedented money-printing are creating ideal conditions for the ultimate inflation hedge: gold. And that's making junior gold equities the go-to sector as the metal rapidly approaches its all-time high.

Amidst all this, one junior gold explorer with a nascent exploration breakthrough could soar as the gold bull market moves into its next phase.

New Brunswick Could Host Large New Gold System

Bona fide new discoveries with district potential are rare. Participating early in one could be a life-changing event.

That's what makes X-Terra Resources Inc. (XTT:TSX.V; XTRRF:OTCMKTS; XTR:FSE) such a compelling investment right now. XTT shares are a Strong BUY, with the potential to double in the next 6–12 months.

Here's my rationale…

Its top two projects are in neighboring Canadian provinces, both among the highest-ranking gold mining jurisdictions globally.

In early March, X-Terra completed its inaugural drill program over the Grog and Northwest Properties in the province of New Brunswick along the McKenzie Fault. It comprised 1,904 meters over 16 holes.

Initial results are in, and they're impressive.

Hole GRG-20-012 identified gold mineralization over a significant width. One interval averaged 0.41 g/t gold over 36 meters, including 0.46 g/t gold over 31 meters and 7.59 g/t gold over 0.6 meters. The company points out that 6 of the remaining holes returned mineralized intervals between 0.1 g/t gold and 0.35 g/t gold.

X-Terra President and CEO Michael Ferreira said, "This is a significant exploration breakthrough, and reinforces our expectations that a large epithermal system is present. While more in-depth geological work, which includes drilling is needed, it remains evident that the 11 holes (1570 metres drilled) only covered a very small fraction of the targeted environment. Reaching a significant mineralized interval this shallow (From 107 metres to 143 metres, in GRG-20-012) is a milestone we were relentlessly pursuing after completing the limited field exploration programs based predominately on roadside trenching. The information obtained in this program will allow the detailed follow up on the Grog Target but also allow the company to refine and generate more high priority targets carrying the same geological characteristics to that of the Grog target. This provides a monumental shift moving forward."

HIGHLIGHTS FROM HOLE GRG-20-012

The beauty of this impressive drill hole intercept is its signature, which contains a wide alteration halo associated with sulfidation and quartz veining. Based on the geophysical data, they will be able to track the gold bearing system at depth using an advanced data processing approach combined with their geological knowledge.

The exploration team can now use the signature to formulate similar drill targets elsewhere on the property, with the potential for similar results.

Clearly, X-Terra's diligent, methodical and scientific approach has begun to pay off. Experience combined with a skilled overlay of induced polarization, magnetic surveys, sampling and trenching helped achieve this recent success.

Back in 2017, the company discovered high grade gold occurrences. That was followed up with further work, which delivered extensive anomalies scattered over roughly 30 km along the McKenzie Gulch regional Fault.

Their geologists then engaged a quick exploration cycle over the next 18 months, starting with an orientation geophysics survey, followed by trenching and drilling. They now have an initial model in progress, which involves an extensive magmatic hydrothermal system, and the targets generated so far are pluri-kilometric.

X-Terra is contemplating that it could be onto a brand new regional gold trend.

Such outstanding recent drill intercepts make for an even more exciting outlook. That's because future exploration targets will be chosen with a better understanding of the geological sequence. And that should improve the odds of more successful drill results.

But perhaps the biggest takeaway from hole GRG-20-012 is the suggestion that it demonstrates real potential for a large epithermal system. And that could mean a whole lot of gold lies beneath, something further exploration will answer.

Quebec Offers Huge Promise Near Large Developing Gold Mine

Despite the exciting outlook offered by the Grog area located in New Brunswick, X-Terra is far from being a one-trick pony.

Also bursting with massive untapped potential is the Troilus East Property, located in north-central Quebec.

X-Terra's Troilus East project is immediately adjacent to Troilus Gold Corp.'s former producing gold-copper mine. Even after 15 years of historic production, the Troilus Gold Project currently boasts 4.71 million ounces of gold equivalent in the Indicated category, plus 1.76 million ounces of gold equivalent in the Inferred category.

Early last year, X-Terra announced the completion of a high-resolution magnetic survey on the Troilus-East property. Management continues to advance the project, using the same diligent and methodical scientific approach that has brought success to the Grog discovery. XTT will be using magnetic signatures to perform follow-up work, looking to identify geological contexts with characteristics similar to those of the Troilus gold-copper mineral deposit.

Since tripling its land position, X-Terra has locked up the largest adjacent land claims to Troilus Gold of any public company.

That's exciting, as Troilus Gold is considered by some as the largest—or at least one of the largest—undeveloped gold deposits in North America. And that could well make X-Terra a future target should Troilus Gold or other players look to lock up more of the adjacent land.

People and Projects Offer Massive Potential

As is often the case, people are as important to a junior explorer's success as its properties. As a former professional motorcycle racer, X-Terra President and CEO Michael Ferreira saw the potential of resource exploration to create immense value for shareholders. Now living full-time in the Quebec mining town of Rouyn Noranda, Ferreira has judiciously curated a winning team.

Dr. Michael Byron, Ph.D., P.Geo. and a company director, has thirty years of field work, research and senior management positions across gold, base-metals, diamond and gemstone exploration. He was instrumental in re-discovering Falco Resources' leading asset, the Horne 5 deposit.

A testament to the quality of management is XTT's rare combination of tight share structure and quality projects. On a fully diluted basis, there are just 80 million shares outstanding, with management's skin in the game representing 6% of ownership.

As I see it, X-Terra's combination of quality management with exceptional high potential projects is starting to bear fruit. Its New Brunswick-located Grog and Northwest project, along with its Troilus East project located in Quebec, are highly prospective.

Given that the global fiscal and monetary response to the coronavirus has generated a tsunami of money printing, the gold market is kicking into high gear.

That sets up the perfect storm for X-Terra, making it a Strong BUY. With its outstanding initial drill results at the Grog property and the remarkable potential at Troilus East, I can easily see XTT double its market cap in the next 6–12 months, perhaps sooner.

In my view these are the early days of a string of successful exploration results, making XTT.V radically undervalued, for now.

Peter Krauth is a former portfolio adviser and a 20-year veteran of the resource market, with special expertise in energy, metals and mining stocks. He has been editor of a widely circulated resource newsletter, and contributed numerous articles to Kitco.com, BNN Bloomberg and the Financial Post. Krauth holds a Master of Business Administration from McGill University and is headquartered in resource-rich Canada.

Disclosure:
1) Peter Krauth: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: X-Terra Resources. My company has a financial relationship with the following companies mentioned in this article: None. I determined which companies would be included in this article based on my research and understanding of the sector.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: X-Terra Resources. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with X-Terra Resources. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of X-Terra Resources. Please click here for more information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of X-Terra Resources, a company mentioned in this article.

( Companies Mentioned: XTT:TSX.V; XTRRF:OTCMKTS; XTR:FSE, )

The 2020 State of Disbursements: APAC Outlook Report by Rapyd...

A bold national initiative is needed to reduce the enormous health burden of sexually transmitted diseases (STDs) in the United States, according to a new report from a committee of the Institute of Medicine.

More targeted aircraft testing and simulation should be conducted to uncover design characteristics in new flight control systems that -- in rare circumstances -- may mislead pilots and result in unstable or dangerous flight conditions, says a new report by a National Research Council committee.

A series of secret tests conducted by the U.S. Army in the 1950s and 1960s did not expose residents of the United States and Canada to chemical levels considered harmful, according to a new report from a committee of the National Research Council.

The Council of the National Academy of Sciences (NAS) is concerned about the confusion caused by a petition being circulated via a letter from a former president of this Academy.

Good morning and welcome. There has been unprecedented interest in recent years about whether marijuana or its constituent compounds should be used as medicine. Since 1996, voters in seven states have approved the medical use of marijuana.

Incineration is widely used in the United States to reduce the volume of waste. Hundreds of incinerators -- including industrial kilns, boilers, and furnaces -- combust municipal and hazardous waste, while many more are used to burn medical waste.

Reducing one of the nations leading causes of death and injury – medical errors – will require rigorous changes throughout the health care system, including mandatory reporting requirements.

No justification currently exists for completely abandoning chemical pesticides, says a new report from the National Academies National Research Council.

American students progress toward proficiency in mathematics requires major changes in instruction, curricula, and assessment in the nations schools, says a new report from the National Research Council of the National Academies.

The nations health care industry has foundered in its ability to provide safe, high-quality care consistently to all Americans, says a new report from the Institute of Medicine of the National Academies. Reorganization and reform are urgently needed to fix what is now a disjointed and inefficient system.

By expending too many resources to inspect cleaner low-emitting vehicles, coupled with a lack of effective ways to deal with the dirtiest ones, states are missing opportunities to reduce air pollution.

Representatives from academies and research organizations around the world sent messages of condolence and support to members, officials and staff of the U.S. National Academies in the wake of terrorist attacks on the World Trade Center and the Pentagon. The following are excerpts from some of these messages.

Good morning. I am Richard Bonnie, chair of the Committee on Developing a Strategy to Reduce and Prevent Underage Drinking.

Welcome to the public release of the latest Institute of Medicine report on the quality of health care in America.